Research programme: TRPV1 receptor antagonists - Renovis/Pfizer

Drug Profile

Research programme: TRPV1 receptor antagonists - Renovis/Pfizer

Alternative Names: TRPV1 antagonists - Renovis/Pfizer; Vanilloid receptor antagonists - Renovis/Pfizer

Latest Information Update: 03 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer; Renovis
  • Developer Evotec AG; Pfizer
  • Class Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Pain; Urinary incontinence

Most Recent Events

  • 27 Mar 2013 Pfizer terminates its collaboration for TRPV1 receptor antagonists in USA
  • 25 May 2011 Preclinical development is ongoing in USA
  • 03 May 2008 Renovis has been acquired by Evotec AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top